• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用自然杀伤细胞功能治疗泌尿生殖系统癌症。

Harnessing Natural Killer Cell Function for Genitourinary Cancers.

机构信息

Department of Hematology & Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Hess CSM Building 1470 Madison Avenue, New York, NY 10029, USA.

Department of Hematology & Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, 1470 Madison Avenue, New York, NY 10029, USA.

出版信息

Urol Clin North Am. 2020 Nov;47(4):433-442. doi: 10.1016/j.ucl.2020.07.002. Epub 2020 Sep 2.

DOI:10.1016/j.ucl.2020.07.002
PMID:33008494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7992041/
Abstract

Natural killer (NK) cells are potently cytolytic innate lymphocytes involved in the immune surveillance of tumors and virally infected cells. Although much progress has been made in manipulating the ability of T cells to recognize and eliminate tumors, a comprehensive understanding of NK-cell infiltration into solid tumors, and their amenability to immunomodulation, remains incomplete. This article discusses recent studies showing that urologic tumors are infiltrated by NK cells and that these NK cells are often dysfunctional, but that strategies interfering with inhibitory axes have significant potential to alleviate this dysfunction.

摘要

自然杀伤 (NK) 细胞是一种强有力的细胞溶解性先天淋巴细胞,参与肿瘤和病毒感染细胞的免疫监视。尽管在操纵 T 细胞识别和消除肿瘤的能力方面已经取得了很大进展,但对 NK 细胞浸润实体瘤及其对免疫调节的易感性的全面理解仍不完整。本文讨论了最近的研究表明,泌尿系统肿瘤浸润 NK 细胞,这些 NK 细胞通常功能失调,但干扰抑制轴的策略具有显著缓解这种功能失调的潜力。

相似文献

1
Harnessing Natural Killer Cell Function for Genitourinary Cancers.利用自然杀伤细胞功能治疗泌尿生殖系统癌症。
Urol Clin North Am. 2020 Nov;47(4):433-442. doi: 10.1016/j.ucl.2020.07.002. Epub 2020 Sep 2.
2
Novel immunotherapies in GU malignancies.GU 恶性肿瘤的新型免疫疗法。
Curr Oncol Rep. 2013 Jun;15(3):224-31. doi: 10.1007/s11912-013-0306-8.
3
An Overview of Emerging Immunotargets of Genitourinary Tumors.泌尿生殖系统肿瘤新兴免疫靶点概述
Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649.
4
[Immunotherapy in uropathology].[泌尿病理学中的免疫疗法]
Ann Pathol. 2017 Feb;37(1):90-100. doi: 10.1016/j.annpat.2016.12.015. Epub 2017 Jan 19.
5
Carcinoembryonic antigen in patients with urologic cancers.泌尿系统癌症患者的癌胚抗原
Urol Res. 1973 Oct;1(3):101-5. doi: 10.1007/BF00257371.
6
[The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].[泌尿生殖系统癌症患者自然杀伤细胞活性的研究——从泌尿生殖系统癌的分期和抗肿瘤治疗角度对自然杀伤细胞活性的调查]
Nihon Hinyokika Gakkai Zasshi. 1988 Feb;79(2):239-45. doi: 10.5980/jpnjurol1928.79.2_239.
7
[Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell activity and proliferation of tumor cells].[人自然杀伤(NK)细胞对源自恶性泌尿系统肿瘤的细胞系活性的研究。第3部分:溶链菌制剂对人NK细胞活性及肿瘤细胞增殖的影响]
Nihon Hinyokika Gakkai Zasshi. 1984 Jul;75(7):1124-33. doi: 10.5980/jpnjurol1928.75.7_1124.
8
Combination immunotherapy in genitourinary malignancies.泌尿生殖系统恶性肿瘤的联合免疫疗法。
Curr Opin Urol. 2016 Nov;26(6):523-8. doi: 10.1097/MOU.0000000000000336.
9
[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].[免疫疗法治疗泌尿生殖系统癌症患者:综述与展望]
Bull Cancer. 2017 Apr;104(4):370-379. doi: 10.1016/j.bulcan.2017.01.009. Epub 2017 Feb 23.
10
[Combination radiotherapy-immunotherapy in genitourinary cancer].[泌尿生殖系统癌症的放疗与免疫治疗联合应用]
Cancer Radiother. 2021 Oct;25(6-7):565-569. doi: 10.1016/j.canrad.2021.06.033. Epub 2021 Aug 12.

引用本文的文献

1
Role of the tumor microenvironment in promoting treatment resistance in urothelial carcinoma (Review).肿瘤微环境在促进尿路上皮癌治疗抵抗中的作用(综述)
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13658. Epub 2025 Aug 24.
2
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.膀胱癌中针对自然杀伤细胞的免疫疗法:超越检查点抑制剂
Bladder Cancer. 2023 Jun 27;9(2):125-139. doi: 10.3233/BLC-220109. eCollection 2023.
3
Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.

本文引用的文献

1
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
2
Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?自然杀伤细胞活性能否帮助筛选需要进行前列腺癌活检诊断的患者?
Int Braz J Urol. 2020 Mar-Apr;46(2):244-252. doi: 10.1590/S1677-5538.IBJU.2019.0268.
3
NK cells for cancer immunotherapy.自然杀伤细胞用于癌症免疫疗法。
先天性淋巴细胞在膀胱癌中的作用:从作用机制到免疫治疗。
Cancer Immunol Res. 2024 Feb 2;12(2):149-160. doi: 10.1158/2326-6066.CIR-23-0414.
4
WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.WTAP 增强了 YTHDF2 在膀胱癌中引起的 SYTL1 mRNA 的不稳定性。
Histol Histopathol. 2024 May;39(5):633-646. doi: 10.14670/HH-18-671. Epub 2023 Oct 23.
5
Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.转移性去势抵抗性前列腺癌患者接受恩扎卢胺治疗后的自然杀伤细胞活性。
Sci Rep. 2023 Oct 10;13(1):17144. doi: 10.1038/s41598-023-43937-7.
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. doi: 10.1038/s41573-019-0052-1. Epub 2020 Jan 6.
4
Single-Cell Transcriptomic Map of the Human and Mouse Bladders.人类和小鼠膀胱的单细胞转录组图谱。
J Am Soc Nephrol. 2019 Nov;30(11):2159-2176. doi: 10.1681/ASN.2019040335. Epub 2019 Aug 28.
5
Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.自然杀伤细胞活性与接受前列腺活检的老年男性前列腺癌风险。
Cancer Epidemiol. 2019 Oct;62:101578. doi: 10.1016/j.canep.2019.101578. Epub 2019 Aug 1.
6
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.成纤维细胞生长因子受体 3 改变与转移性尿路上皮癌患者对 PD-1/PD-L1 阻断的反应。
Eur Urol. 2019 Nov;76(5):599-603. doi: 10.1016/j.eururo.2019.06.025. Epub 2019 Jul 1.
7
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.抑制 EZH2 可诱导肌肉浸润性膀胱癌中 NK 细胞介导的分化和死亡。
Cell Death Differ. 2019 Oct;26(10):2100-2114. doi: 10.1038/s41418-019-0278-9. Epub 2019 Jan 28.
8
Intratumoral CD56 natural killer cells are associated with improved survival in bladder cancer.肿瘤内CD56自然杀伤细胞与膀胱癌患者生存率提高相关。
Oncotarget. 2018 Nov 23;9(92):36492-36502. doi: 10.18632/oncotarget.26362.
9
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.抗 NKG2A mAb 是一种检查点抑制剂,通过释放 T 细胞和 NK 细胞来促进抗肿瘤免疫。
Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29.
10
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.自然杀伤细胞-树突状细胞轴定义了检查点治疗反应性肿瘤微环境。
Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25.